Jana Engelmann1, Ulf Manuwald1, Constanze Rubach1, Joachim Kugler1, Andreas L Birkenfeld2,3, Markolf Hanefeld3, Ulrike Rothe4. 1. Health Sciences/Public Health, Faculty of Medicine, TUD, Fetscherstraße 74, D-01307, Dresden, Germany. 2. Medical Clinic III, University Clinic, Faculty of Medicine, TUD, Fetscherstraße 74, D-01307, Dresden, Germany. 3. Study Center Prof. Hanefeld, Research for Metabolic Vascular Syndrome, GWT-TUD GmbH, Fiedlerstraße 34, D-01307, Dresden, Germany. 4. Health Sciences/Public Health, Faculty of Medicine, TUD, Fetscherstraße 74, D-01307, Dresden, Germany. ulrike.rothe@tu-dresden.de.
Abstract
UNLABELLED: We aimed to review and summarize the evidence from accomplished trials analyzing factors influencing mortality in patients with T2DM and to provide some recommendations for targets and treatment in the European region. The following databases were searched for relevant trials: PubMed and the Cochrane Library. Of 3.806 citations, 134 trials met our inclusion criteria. RESULTS: The reduction in lifetime for 65 + -years-old patients having less than 10 years T2DM amounts to 1.8 years. Having T2DM for more than 10 years lifetime will be reduced by 2.7 years. However, the lifetime shortening factor of T2DM will even be stronger for 40 + -years-old patients at onset. Males will lose 11.6 years of life and 18.6 QUALYs. T2DM among females will reduce life by 14 QUALYs by 22 years. From a statistical point of view, the highest mortality rate will occur in an over 55-years-old European smoking and non-compliant diabetic woman with alcohol abuse living in a rural area with a low level of education and a low socio-economic status. Furthermore, other co-morbidities such as cardiovascular diseases, gout, and depression affect mortality. Additionally, mortality will increase with a BMI over 35 and also with a BMI under 20-25. This refers to the obesity paradox indicating a higher mortality rate among normal weight patients with T2DM compared to overweight patients with T2DM. HbA1c-levels between 6.5 % and 7 % are associated with the lowest impact on mortality.
UNLABELLED: We aimed to review and summarize the evidence from accomplished trials analyzing factors influencing mortality in patients with T2DM and to provide some recommendations for targets and treatment in the European region. The following databases were searched for relevant trials: PubMed and the Cochrane Library. Of 3.806 citations, 134 trials met our inclusion criteria. RESULTS: The reduction in lifetime for 65 + -years-old patients having less than 10 years T2DM amounts to 1.8 years. Having T2DM for more than 10 years lifetime will be reduced by 2.7 years. However, the lifetime shortening factor of T2DM will even be stronger for 40 + -years-old patients at onset. Males will lose 11.6 years of life and 18.6 QUALYs. T2DM among females will reduce life by 14 QUALYs by 22 years. From a statistical point of view, the highest mortality rate will occur in an over 55-years-old European smoking and non-compliant diabeticwoman with alcohol abuse living in a rural area with a low level of education and a low socio-economic status. Furthermore, other co-morbidities such as cardiovascular diseases, gout, and depression affect mortality. Additionally, mortality will increase with a BMI over 35 and also with a BMI under 20-25. This refers to the obesity paradox indicating a higher mortality rate among normal weight patients with T2DM compared to overweight patients with T2DM. HbA1c-levels between 6.5 % and 7 % are associated with the lowest impact on mortality.
Entities:
Keywords:
Determinants; Life expectancy; Lifetime; Mortality; Survival; T2DM
Authors: Amanda J Cox; Fang-Chi Hsu; Barry I Freedman; David M Herrington; Michael H Criqui; J Jeffrey Carr; Donald W Bowden Journal: Diabetes Care Date: 2014-07-02 Impact factor: 19.112
Authors: C K H Wong; W C W Wong; Y F Wan; A K C Chan; K L Chung; F W K Chan; C L K Lam Journal: Diabetes Obes Metab Date: 2014-10-20 Impact factor: 6.577
Authors: Kornelis J J van Hateren; Steven H Hendriks; Klaas H Groenier; Stephan J L Bakker; Henk J G Bilo; Nanne Kleefstra; Gijs W D Landman Journal: J Hypertens Date: 2015-06 Impact factor: 4.844
Authors: Kamlesh Khunti; Melanie Davies; Azeem Majeed; Brian Larsen Thorsted; Michael Lyng Wolden; Sanjoy K Paul Journal: Diabetes Care Date: 2014-12-09 Impact factor: 19.112
Authors: Manuel Franco; Usama Bilal; Pedro Orduñez; Mikhail Benet; Alain Morejón; Benjamín Caballero; Joan F Kennelly; Richard S Cooper Journal: BMJ Date: 2013-04-09
Authors: Matti Uusitupa; Markku Peltonen; Jaana Lindström; Sirkka Aunola; Pirjo Ilanne-Parikka; Sirkka Keinänen-Kiukaanniemi; Timo T Valle; Johan G Eriksson; Jaakko Tuomilehto Journal: PLoS One Date: 2009-05-21 Impact factor: 3.240
Authors: Tone Britt Hortemo Osthus; Nanna von der Lippe; Lis Ribu; Tone Rustøen; Torbjørn Leivestad; Toril Dammen; Ingrid Os Journal: BMC Nephrol Date: 2012-08-03 Impact factor: 2.388
Authors: M A Daniels; C Kan; D M Willmes; K Ismail; F Pistrosch; D Hopkins; G Mingrone; S R Bornstein; A L Birkenfeld Journal: Pharmacogenomics J Date: 2016-07-19 Impact factor: 3.550
Authors: Sylvia Drazilova; Martin Janicko; Lubomir Skladany; Pavol Kristian; Marian Oltman; Maria Szantova; Dusan Krkoska; Eva Mazuchova; Lubica Piesecka; Veronika Vahalova; Marek Rac; Ivan Schreter; Ladislav Virag; Tomas Koller; Adriana Liptakova; Miriam Ondrasova; Peter Jarcuska Journal: Can J Gastroenterol Hepatol Date: 2018-10-03
Authors: Philip Tonnesen; Jacob L Marott; Børge Nordestgaard; Stig Egil Bojesen; Peter Lange Journal: Tob Induc Dis Date: 2019-10-07 Impact factor: 2.600
Authors: Irene Escribano-Lopez; Noelia Diaz-Morales; Francesca Iannantuoni; Sandra Lopez-Domenech; Aranzazu M de Marañon; Zaida Abad-Jimenez; Celia Bañuls; Susana Rovira-Llopis; Jose R Herance; Milagros Rocha; Victor M Victor Journal: Sci Rep Date: 2018-10-26 Impact factor: 4.379
Authors: Volkert Siersma; Rasmus Køster-Rasmussen; Christine Bruun; Niels de Fine Olivarius; Audun Brunes Journal: BMJ Open Diabetes Res Care Date: 2019-10-11
Authors: Tina Schumann; Jörg König; Christian von Loeffelholz; Daniel F Vatner; Dongyan Zhang; Rachel J Perry; Michel Bernier; Jason Chami; Christine Henke; Anica Kurzbach; Nermeen N El-Agroudy; Diana M Willmes; Dominik Pesta; Rafael de Cabo; John F O Sullivan; Eric Simon; Gerald I Shulman; Bradford S Hamilton; Andreas L Birkenfeld Journal: Commun Biol Date: 2021-07-01